Ownership and insider activity for BillionToOne, Inc. (BLLN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection.
Price
| Price | $109.06 |
| Market Cap | $5.0B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-28 | Atay Oguzhan | M-Exempt | 8,333 | $23K |
| 2026-09-28 | Atay Oguzhan | S-Sale | 2,666 | $322K |
| 2026-09-28 | Atay Oguzhan | M-Exempt | 8,333 | $23K |
| 2026-09-28 | Atay Oguzhan | S-Sale | 8,333 | $1.0M |
| 2026-09-24 | Tsao David | M-Exempt | 3,333 | $9K |
| 2026-09-24 | Tsao David | M-Exempt | 3,333 | $9K |
| 2026-09-24 | Tsao David | S-Sale | 3,333 | $417K |
| 2026-09-24 | ten Bosch John Roderick | S-Sale | 1,416 | $170K |
| 2026-09-21 | ten Bosch John Roderick | S-Sale | 1,416 | $151K |
| 2026-09-17 | Lynch Thomas P. | M-Exempt | 19,384 | $168K |
Balance Sheet (10y)
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Cash & Equivalents | $97.3M | $191.5M | $496.0M |
| Short-term Investments | 0 | 0 | 0 |
| Receivables | $9.1M | $24.7M | $41.6M |
| Inventory | $7.2M | $8.7M | $17.5M |
| Total Current Assets | $115.5M | $227.8M | $560.6M |
| Property, Plant & Equipment | $73.9M | $68.8M | $67.1M |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Total Assets | $191.7M | $302.1M | $632.7M |
| Accounts Payable | $3.2M | $4.3M | $7.2M |
| Short-term Debt | $53.7M | $6.2M | $5.6M |
| Total Current Liabilities | $66.8M | $28.4M | $48.0M |
| Long-term Debt | $35.0M | $51.5M | $57.2M |
| Total Liabilities | $161.2M | $134.3M | $152.5M |
| Retained Earnings | -$240.6M | -$282.2M | -$274.7M |
| Total Equity | $30.5M | $167.8M | $480.1M |
| Total Debt | $146.3M | $109.4M | $108.9M |
| Net Debt | $49.1M | -$82.1M | -$387.1M |
| Working Capital | $48.7M | $199.4M | $512.6M |
Financial Health
| Debt / Equity | 0.27 |
| Current Ratio | 11.69 |
Profitability
| Return on Equity | 7.87% |
| Return on Invested Capital | 6.33% |
| Return on Assets | 4.59% |
| Gross Margin | 71.27% |
| Operating Margin | 10.90% |
| Net Margin | 8.43% |
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BLLN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks